416 related articles for article (PubMed ID: 30291373)
1. FDG PET/CT for assessing tumour response to immunotherapy : Report on the EANM symposium on immune modulation and recent review of the literature.
Aide N; Hicks RJ; Le Tourneau C; Lheureux S; Fanti S; Lopci E
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):238-250. PubMed ID: 30291373
[TBL] [Abstract][Full Text] [Related]
2.
Prigent K; Aide N
PET Clin; 2020 Jan; 15(1):1-10. PubMed ID: 31735296
[TBL] [Abstract][Full Text] [Related]
3. Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [
Lopci E; Hicks RJ; Dimitrakopoulou-Strauss A; Dercle L; Iravani A; Seban RD; Sachpekidis C; Humbert O; Gheysens O; Glaudemans AWJM; Weber W; Wahl RL; Scott AM; Pandit-Taskar N; Aide N
Eur J Nucl Med Mol Imaging; 2022 Jun; 49(7):2323-2341. PubMed ID: 35376991
[TBL] [Abstract][Full Text] [Related]
4.
Cherk MH; Nadebaum DP; Barber TW; Beech P; Haydon A; Yap KS
J Med Imaging Radiat Oncol; 2022 Jun; 66(4):483-494. PubMed ID: 35191204
[No Abstract] [Full Text] [Related]
5. [Expert consensus on assessing tumor response to immune checkpoint inhibitors by PET/CT (2020 Edition)].
PET Group, Chinese Society of Nuclear Medicine
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):697-705. PubMed ID: 32988149
[TBL] [Abstract][Full Text] [Related]
6. Perspectives on joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards for [
Lopci E; Aide N; Dimitrakopoulou-Strauss A; Dercle L; Iravani A; Seban RD; Sachpekidis C; Humbert O; Gheysens O; Glaudemans AWJM; Weber WA; Van den Abbeele AD; Wahl RL; Scott AM; Pandit-Taskar N; Hicks RJ
Cancer Imaging; 2022 Dec; 22(1):73. PubMed ID: 36539908
[TBL] [Abstract][Full Text] [Related]
7. SNMMI Procedure Standard/EANM Practice Guideline on Pediatric
Vali R; Alessio A; Balza R; Borgwardt L; Bar-Sever Z; Czachowski M; Jehanno N; Kurch L; Pandit-Taskar N; Parisi M; Piccardo A; Seghers V; Shulkin BL; Zucchetta P; Lim R
J Nucl Med; 2021 Jan; 62(1):99-110. PubMed ID: 33334912
[TBL] [Abstract][Full Text] [Related]
8. PET/Computed Tomography Transformation of Oncology: Immunotherapy Assessment.
Ghodsi A; Hicks RJ; Iravani A
PET Clin; 2024 Apr; 19(2):291-306. PubMed ID: 38199917
[TBL] [Abstract][Full Text] [Related]
9. Novelties from the Joint EANM/SNMMI/ANZSNM Guidelines on Immunotherapy.
Lopci E; Castello A; Filippi L
Cancer Biother Radiopharm; 2023 May; 38(4):211-215. PubMed ID: 36730788
[TBL] [Abstract][Full Text] [Related]
10. Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 2: The Role of Novel PET Agents.
Iravani A; Hicks RJ
J Nucl Med; 2020 Nov; 61(11):1553-1559. PubMed ID: 32887755
[TBL] [Abstract][Full Text] [Related]
11. Immune PET Imaging.
Iyalomhe O; Farwell MD
Radiol Clin North Am; 2021 Sep; 59(5):875-886. PubMed ID: 34392924
[TBL] [Abstract][Full Text] [Related]
12. Monitoring of patients with metastatic melanoma treated with immune checkpoint inhibitors using PET-CT.
Dimitrakopoulou-Strauss A
Cancer Immunol Immunother; 2019 May; 68(5):813-822. PubMed ID: 30123922
[TBL] [Abstract][Full Text] [Related]
13. Role of FDG PET/CT in monitoring treatment response in patients with invasive fungal infections.
Ankrah AO; Span LFR; Klein HC; de Jong PA; Dierckx RAJO; Kwee TC; Sathekge MM; Glaudemans AWJM
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):174-183. PubMed ID: 30343434
[TBL] [Abstract][Full Text] [Related]
14. Immune-mediated Disease in Ipilimumab Immunotherapy of Melanoma with FDG PET-CT.
Wachsmann JW; Ganti R; Peng F
Acad Radiol; 2017 Jan; 24(1):111-115. PubMed ID: 27818005
[TBL] [Abstract][Full Text] [Related]
15.
Hicks RJ; Iravani A; Sandhu S
PET Clin; 2020 Jan; 15(1):11-22. PubMed ID: 31735298
[TBL] [Abstract][Full Text] [Related]
16. [Procedure guidelines for whole-body 18F-FDG PET and PET/CT in children with malignant diseases].
Franzius C; Stauss J; Pfluger T; Juergens KU; Kluge R; Amthauer H; Juergens H; Henze G; Stoever B; Hahn K
Nuklearmedizin; 2010; 49(6):225-33; quiz N60-1. PubMed ID: 20617279
[TBL] [Abstract][Full Text] [Related]
17. FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls.
Cho SY; Huff DT; Jeraj R; Albertini MR
Semin Nucl Med; 2020 Nov; 50(6):518-531. PubMed ID: 33059821
[TBL] [Abstract][Full Text] [Related]
18. It's About Quality, Not Quantity: Qualitative FDG PET/CT Criteria for Therapy Response Assessment in Clinical Practice.
Banks KP; Peacock JG; Gusman M; Clemenshaw MN
AJR Am J Roentgenol; 2020 Aug; 215(2):313-324. PubMed ID: 32551905
[No Abstract] [Full Text] [Related]
19.
Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D
Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374
[TBL] [Abstract][Full Text] [Related]
20. Methods to delineate tumour for radiotherapy by fluorodeoxyglucose positron emission tomography.
Gardin I
Cancer Radiother; 2020 Aug; 24(5):418-422. PubMed ID: 32507519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
